SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

Ítems similars

• Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
  per: Gadelha, Mônica, et al.
  Publicat: (2020)
• SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
  per: Coopmans, Eva, et al.
  Publicat: (2019)
• Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
  per: Colao, Annamaria, et al.
  Publicat: (2015)
• MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
  per: Chiloiro, Sabrina, et al.
  Publicat: (2020)
• SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
  per: Geer, Eliza, et al.
  Publicat: (2019)